Level of Serum Lactate Dehydrogenase in Immune Thrombocytopenia

NCT ID: NCT07046013

Last Updated: 2025-07-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-08-31

Study Completion Date

2027-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Assessment of relation between serum lactate dehydrogenase and immune thrombocytopenia

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Immune thrombocytopenia is an autoimmune disorder defined by a significantly reduced number of platelets in blood circulation.

Lactate dehydrogenase is a group of oxidoreductase isoenzymes catalyzing the reversible reaction between pyruvate and lactate.

The LDH was found to be moderately high in patients with immune thrombocytopenia at the time of diagnosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Immune Thrombocytopenia (ITP)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lactate dehydrogenase

It's elevation at the time of diagnosis

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Thrombocytopenia patients at the time of diagnosis.

Exclusion Criteria

* bone fractures \_ bone diseases\_ malignancy
Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sohag University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Shimaa Mahmoud Fahmy

Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Shaimaa Mahmoud Fahmy, Resident doctor

Role: CONTACT

01149586292

Hassnaa Ahmed Abo elwafa, Prof.Dr

Role: CONTACT

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Soh-Med-25-5-7MS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.